Alpha Tau Medical (DRTS) Expected to Announce Quarterly Earnings on Tuesday

Alpha Tau Medical (DRTS) is projected to report Q3 2025 earnings of ($0.12) per share on November 18, 2025. The clinical-stage oncology company, which recently saw its stock open down 4.1% at $3.71, maintains a market capitalization of $314.68 million and an average analyst "Hold" rating with a $9.00 price target, despite conflicting individual analyst recommendations. Institutional activity includes Envestnet Asset Management acquiring a new position in Q3, contributing to the 2.65% institutional ownership.

Analysis

Alpha Tau Medical (DRTS) is scheduled to release its Q3 2025 results on November 18th, with analysts projecting an earnings per share of ($0.12). The stock recently experienced a 4.1% decline, opening at $3.71, indicating some market caution ahead of the earnings call. This follows a period where the stock traded between a 12-month low of $2.20 and a high of $4.69.

Despite a negative price-to-earnings ratio of -7.73, which highlights current unprofitability, the company demonstrates robust financial health in terms of liquidity and leverage. DRTS boasts a quick ratio of 5.81 and a current ratio of 10.52, coupled with a very low debt-to-equity ratio of 0.07, suggesting a strong balance sheet to support its clinical-stage operations.

Analyst sentiment is notably divided, with HC Wainwright reissuing a "buy" rating and a $9.00 target price, while Weiss Ratings and Wall Street Zen have issued "sell" ratings. This divergence contributes to an average "Hold" rating and a consensus target price of $9.00, which implies significant upside from the current trading price.

Institutional interest is evidenced by Envestnet Asset Management Inc.'s new position of 13,765 shares acquired in Q3, valued at approximately $62,000. Overall, hedge funds and other institutional investors collectively own 2.65% of Alpha Tau Medical's stock, indicating a measured but present level of professional investment in the oncology therapeutics firm.

Key Decisions for Investors

• Investors should closely monitor Alpha Tau Medical's Q3 2025 earnings report for any deviation from the ($0.12) EPS consensus and for updates on its Alpha DaRT clinical trial progress.
• Evaluate the sustainability of the company's strong liquidity and low debt in the context of persistent unprofitability and the long development cycles inherent in clinical-stage biotechnology.
• Consider the implications of the mixed analyst ratings and the significant upside implied by the $9.00 average price target, paying attention to whether these ratings are re-affirmed or adjusted post-earnings.